Patents by Inventor Sanjeeva Reddy
Sanjeeva Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11784910Abstract: A method and system are disclosed, for using Intermediate System to Intermediate System, IS-IS, as control plane for Shortest Path Bridging, SPB, in a network comprising at least a Service Provider Network, SPN (101), and at least two Backbone Edge Bridges, BEBs (121i), connected to the SPN (101). The method comprises, and the BEBs are configured to: forming adjacency between BEBs through LAN Hellos, electing one of the BEBs as a Designated IS, DIS, and an emulated pseudonode, all BEBs creating and flooding non-pseudonode level-1 LSPs, the DIS creating and flooding a Pseudonode level-1 ESP, and periodically sending Complete Sequence Number PDUs, CSNPs, to the other BEBs, and running Shortest Path First, SPF, to calculate the shortest path in the network between BEBs.Type: GrantFiled: June 24, 2020Date of Patent: October 10, 2023Assignee: ALE USA INC.Inventors: Sanjeeva Reddy Yerrapureddy, Pramoda Nallur
-
Publication number: 20230198889Abstract: A method and system are disclosed, for using Intermediate System to Intermediate System, IS-IS, as control plane for Shortest Path Bridging, SPB, in a network comprising at least a Service Provider Network, SPN (101), and at least two Backbone Edge Bridges, BEBs (121i), connected to the SPN (101). The method comprises, and the BEBs are configured to: forming adjacency between BEBs through LAN Hellos, electing one of the BEBs as a Designated IS, DIS, and an emulated pseudonode, all BEBs creating and flooding non-pseudonode level-1 LSPs, the DIS creating and flooding a Pseudonode level-1 ESP, and periodically sending Complete Sequence Number PDUs, CSNPs, to the other BEBs, and running Shortest Path First, SPF, to calculate the shortest path in the network between BEBs.Type: ApplicationFiled: June 24, 2020Publication date: June 22, 2023Inventors: Sanjeeva Reddy YERRAPUREDDY, Pramoda NALLUR
-
Publication number: 20230027072Abstract: The present application provides improved compositions, methods, kits and dosing regimens for the use of heterocyclic compounds and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, or stereoisomers thereof. These compositions, methods, kits and dosing regimens are useful for modulating ERK1/2. By administering to a subject in need a therapeutically effective amount of one or more of the compounds of Formulae (I-III) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or stereoisomer thereof, or compositions of these, wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds and methods are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway or which are treatable by inhibiting Erk 1/2. A variety of conditions can be treated using these compounds and methods and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: October 22, 2020Publication date: January 26, 2023Inventors: Sanjeeva REDDY, Louis DENIS, Niranjan RAO, Helen USANSKY, Dana KESSLER
-
Publication number: 20210113578Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: November 5, 2020Publication date: April 22, 2021Inventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Patent number: 10912779Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: January 24, 2019Date of Patent: February 9, 2021Assignee: Asana BioSciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Patent number: 10869872Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: January 24, 2019Date of Patent: December 22, 2020Assignee: Asana BioSciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Publication number: 20190151327Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: January 24, 2019Publication date: May 23, 2019Inventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hosahalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Patent number: 10226468Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: April 28, 2017Date of Patent: March 12, 2019Assignee: Asana BioSciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Subramanya Hoshalli, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Publication number: 20190014040Abstract: An edge network node and a method of configuring a service are disclosed. A virtualized routing and forwarding (VRF) instance is defined for a customer at the edge network node. The edge network node also defines a service identifier. The edge network node associates the VRF instance with the service identifier and with a routing table entry. The routing table entry comprises a set of destination IP addresses and a backbone IP address, which may be an address of a peer edge network node. When the edge network node receives a packet from the customer, it encapsulates the packet in a tunnel and forwards it on a backbone network toward the peer edge network node. The edge network node may associate a plurality of routing table entries with a service, may define a plurality of services for the customer and may define services for a plurality of customers.Type: ApplicationFiled: September 14, 2018Publication date: January 10, 2019Inventors: Sanjeeva Reddy YERRAPUREDDY, Pramoda NALLUR, Sahil DIGHE
-
Publication number: 20170290838Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: April 28, 2017Publication date: October 12, 2017Inventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Patent number: 9757382Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: GrantFiled: October 11, 2016Date of Patent: September 12, 2017Assignee: Asana BioSciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Publication number: 20170027953Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.Type: ApplicationFiled: October 11, 2016Publication date: February 2, 2017Applicant: Asana Biosciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Patent number: 9499495Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.Type: GrantFiled: April 11, 2014Date of Patent: November 22, 2016Assignee: Asana Biosciences, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Publication number: 20160068496Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8? are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/the disease is cancer.Type: ApplicationFiled: April 11, 2014Publication date: March 10, 2016Applicant: ASANA BIOSCIENCES, LLCInventors: Scott K. Thompson, Roger A. Smith, Sanjeeva Reddy, Tyler M. John, Vijay Kumar Nyavanandi, Hosahalli Subramanya, Vijay Potluri, Sunil Kumar Panigrahi, Prabhakara Rao Nadipalli, Saumitra Sengupta
-
Publication number: 20150334014Abstract: The present subject matter discloses a method for UDP relay in communication networks. In one implementation, a UDP port number included in a header of a message is identified. The method further includes ascertaining the IP address based on a mapping table, where the mapping table includes a list of plurality of UDP port numbers mapping to the IP addresses of corresponding destination servers. Further, the message is modified to obtain a modified message based at least on the IP address. Subsequently, the modified message is unicasted to the destination IP address.Type: ApplicationFiled: October 31, 2013Publication date: November 19, 2015Applicant: ALCATEL LUCENTInventors: Sanjeeva Reddy YERRAPUREDDY, Srivatsa KEDILAYA, Lathakannan ARUMUGAM
-
Patent number: 8041982Abstract: Various apparatuses, methods and systems for a real time clock are disclosed herein. For example, some embodiments provide a real time clock including a clock generator having a first input connected to a clock signal and a second input connected to a time set signal. The clock generator produces a time change signal at an output of the clock generator. Counters, each adapted to track a different unit of time, are connected to the time change signal. The clock generator is adapted to generate a pulse on the time change signal for each pulse of the time set signal, and to generate separate pulses on the time change signal for consecutive pulses on the clock signal and the time set signal.Type: GrantFiled: February 27, 2009Date of Patent: October 18, 2011Assignee: Texas Instruments IncorporatedInventor: Sanjeeva Reddy Pindi
-
Publication number: 20110195110Abstract: Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.Type: ApplicationFiled: December 1, 2006Publication date: August 11, 2011Inventors: Roger Smith, Holia N. Hatoum-Mokdad, Louis David Cantin, Donald E. Bierer, Wenlang Fu, Dhanapalan Nagarathnam, Gaetan Ladouceur, Yamin Wang, Herbert Ogutu, Scot Wilhelm, Ian Taylor, Sanjeeva Reddy, Richard Gedrich, Christopher Carter, Aaron Schmitt, Xiaomei Zhang
-
Publication number: 20100220558Abstract: Various apparatuses, methods and systems for a real time clock are disclosed herein. For example, some embodiments provide a real time clock including a clock generator having a first input connected to a clock signal and a second input connected to a time set signal. The clock generator produces a time change signal at an output of the clock generator. Counters, each adapted to track a different unit of time, are connected to the time change signal. The clock generator is adapted to generate a pulse on the time change signal for each pulse of the time set signal, and to generate separate pulses on the time change signal for consecutive pulses on the clock signal and the time set signal.Type: ApplicationFiled: February 27, 2009Publication date: September 2, 2010Inventor: Sanjeeva Reddy Pindi
-
Patent number: 7435750Abstract: The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: March 8, 2005Date of Patent: October 14, 2008Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, Han-Zhong Zhang, John A. Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Jared Daniel Kuemmerle, Kristin P. Ollis
-
Patent number: 7256219Abstract: The present invention is directed to multifluoro-substituted Chalcones and analogs thereof, represented by the general Formula I: wherein Ar and R6-R10 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: March 14, 2002Date of Patent: August 14, 2007Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, P. Sanjeeva Reddy, John A. Drewe, Bao Ngoc Nguyen, Shailaja Kasibhatla